CONMED Corp Announces Executive and Director Changes
Ticker: CNMD · Form: 8-K · Filed: Sep 20, 2024 · CIK: 816956
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment
TL;DR
CONMED's board and execs are shuffling; Conway out, new officers in.
AI Summary
CONMED Corporation announced on September 16, 2024, changes in its executive team and board of directors. Specifically, the company reported the departure of Director Robert J. Conway, Jr. and the appointment of new officers, including the election of new directors and changes related to compensatory arrangements for certain officers.
Why It Matters
Changes in executive leadership and board composition can signal shifts in company strategy, governance, or future performance.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and operational stability.
Key Numbers
- 001-39218 — SEC File Number (Identifies CONMED Corporation's filing with the SEC.)
- 16-0977505 — IRS Employer Identification No. (Tax identification number for CONMED Corporation.)
Key Players & Entities
- CONMED Corporation (company) — Registrant
- Robert J. Conway, Jr. (person) — Departing Director
- September 16, 2024 (date) — Date of earliest event reported
- 11311 Concept Blvd, Largo, FL 33773 (location) — Principal executive offices
FAQ
Who has departed from CONMED Corporation's board of directors?
Director Robert J. Conway, Jr. has departed from CONMED Corporation's board of directors as of September 16, 2024.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is September 16, 2024.
What is CONMED Corporation's principal executive office address?
CONMED Corporation's principal executive office is located at 11311 Concept Blvd, Largo, FL 33773.
What is the SEC file number for CONMED Corporation?
CONMED Corporation's SEC file number is 001-39218.
What type of apparatus does CONMED Corporation specialize in, according to its SIC code?
According to its Standard Industrial Classification (SIC) code 3845, CONMED Corporation specializes in Electromedical & Electrotherapeutic Apparatus.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-20 17:07:28
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by ch
Filing Documents
- d879960d8k.htm (8-K) — 23KB
- 0001193125-24-222986.txt ( ) — 138KB
- cnmd-20240916.xsd (EX-101.SCH) — 3KB
- cnmd-20240916_lab.xml (EX-101.LAB) — 17KB
- cnmd-20240916_pre.xml (EX-101.PRE) — 11KB
- d879960d8k_htm.xml (XML) — 3KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 11311 Concept Blvd Largo , FL 33773 (Address of principal executive offices) (Zip code) (727) 392-6464 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Rule 12(b) of the Act Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 16, 2024, Eric B. Staves, Vice President, Corporate Controller, informed CONMED Corporation (the "Company") that, effective September 27, 2024, he plans to leave the Company to pursue an executive opportunity. Kimberly A. Lockwood, Director of Financial Reporting & Controls, will serve as Interim Corporate Controller, effective September 30, 2024. Todd W. Garner, Executive Vice President of Finance and Chief Financial Officer, will assume the role of Principal Accounting Officer. Terence M. Berge, retired Vice President, Corporate Controller, continues to serve as Special Advisor to the Company and remains available to support the Company and Ms. Lockwood. Ms. Lockwood joined the Company in 2005 as the Director, Financial Reporting & Controls. Prior to joining the Company, Ms. Lockwood was employed by PricewaterhouseCoopers LLP's Assurance and Business Advisory Services group. Ms. Lockwood is a certified public accountant and holds a Bachelor of Science degree in Accounting from Le Moyne College. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 20, 2024 CONMED CORPORATION (Registrant) By: /s/ Todd W. Garner Name: Todd W. Garner Title: Executive Vice President-Chief Financial Officer